Moderna Reports Positive Interim P-I Data of mRNA-1273 Against COVID-19

 Moderna Reports Positive Interim P-I Data of mRNA-1273 Against COVID-19

Moderna Reports Positive Interim P-I Data of mRNA-1273 Against COVID-19

Shots:

  • Immunogenicity data are available for the 25µg & 100µg dose level (aged 18-55yrs.) after two doses (day 43) and at the 25µg level after one dose (day 29). All the participants are seroconverted by day15 following a single dose, @43day 2wks. following the second dose, at the 25µg, levels of binding Abs were at the levels seen in convalescent sera while at 100µg,  levels of binding Abs exceeded the levels seen in convalescent sera
  • Neutralizing Ab data are available only for the first four participants in each of the 25µg & 100µg dose level cohorts. mRNA-1273 vaccination elicited neutralizing Abs in all eight of participants, as measured by PRNT assays. mRNA-1273 was safe and well-tolerated
  • Following interim P-I data, P-II study will be amended to study two dose levels, 50 & 100 µg, with the aim of selecting a dose for pivotal studies. The anticipated dose for P-III study to be b/w 25µg & 100 µg, expected to be initiated in July

Click here ­to­ read full press release/ article | Ref: Moderna | Image: Moderna

Related News: Moderna’s mRNA-1273 Receives the US FDA’s Fast Track Designation to Treat COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post